Perspective Therapeutics Shares Jump 10% After FDA Fast Track for PSV359 Alpha Therapy

Key highlights

• FDA Fast Track status granted for PSV359 in FAP-positive solitary fibrous tumors (SFTs)
• PSV359 is currently in a Phase 1/2a clinical study for advanced FAP-positive solid tumors
• FAP-alpha expression is associated with poor prognosis in multiple highly prevalent solid tumors
• The company maintains $236.9 million in cash to fund operations through late 2027
• Upcoming Phase 3 initiation for the VMT-alpha-NET program is expected by year-end 2026

What Approval Was Received?

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Perspective Therapeutics lead candidate, PSV359. This designation specifically covers the treatment of adult patients diagnosed with locally advanced unresectable or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs). SFT is a rare malignancy where surgical intervention is often not an option once the disease has progressed or metastasized. PSV359 utilizes a Lead-212 isotope to deliver targeted alpha-particle therapy directly to tumor sites that express the FAP-alpha protein, which is found in the stroma of many epithelial cancers and some sarcomas.

Why This Approval Matters

Fast Track Designation is a significant regulatory tool designed to expedite the clinical development and review of drugs treating serious conditions with unmet medical needs. For Perspective Therapeutics, this status enables more frequent engagement with the FDA throughout the development process. It also creates eligibility for rolling review, where the agency reviews sections of a New Drug Application (NDA) as they are completed rather than waiting for the entire submission. This regulatory pathway is particularly vital for SFT patients, as there are currently no approved therapies specifically targeting FAP-alpha, a protein associated with aggressive cancer phenotypes and poor patient prognosis.

Path to Market

• Continuation of the ongoing Phase 1/2a clinical study evaluating PSV359 in patients with advanced FAP-positive solid tumors
• Utilization of clinical imaging data to pair patient selection with targeted alpha radiopharmaceutical therapy
• Preparation for potential Priority Review or Accelerated Approval filings if clinical benchmarks are met
• Integration of Lead-212 isotope supply chain logistics to support late-stage clinical expansion
• Anticipated milestones for the broader pipeline including a Phase 3 initiation for VMT-alpha-NET by the end of 2026

Financial Context

Perspective Therapeutics reported a robust liquidity position with approximately $236.9 million in cash, cash equivalents, and short-term investments as of August 2026. This capital reserve is projected to sustain planned clinical milestones and general operations into late 2027. The company current market capitalization stands at approximately $280.8 million, reflecting its transition into a pure-play clinical-stage radiopharmaceutical developer. With an RSI of 38.6, the stock is currently trading outside of overbought territory as it approaches major data readouts, including updated Phase 1/2a results for its neuroendocrine tumor program scheduled for presentation in late October 2026.

Down 7.7% since our story on 8 Oct: $2.46 when we broke it → $2.27 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$2.92
15 Sep	$2.73
16 Sep	$2.70
17 Sep	$2.88
18 Sep	$2.88
21 Sep	$2.97
22 Sep	$2.96
23 Sep	$2.62
24 Sep	$2.50
25 Sep	$2.52
28 Sep	$2.50
29 Sep	$2.62
30 Sep	$2.75
1 Oct	$2.72
2 Oct	$2.76
5 Oct	$2.57
6 Oct	$2.36
7 Oct	$2.46
8 Oct	$2.71
9 Oct	$2.66
12 Oct	$2.52
13 Oct	$2.27

Management commentary

“FAP-alpha is a particularly compelling target because of its broad expression across solid tumors and within the tumor microenvironment, creating the potential for PSV359 to address a substantial patient population across multiple cancer types.”

“Fast Track designation for FAP-positive solitary fibrous tumors is an important step in advancing the broader PSV359 program and our strategy of engineering targeted radiopharmaceutical therapy based on the alpha-generating isotope 212Pb to optimize the therapeutic window in oncology.”

Perspective Therapeutics, Inc. · financial snapshot

Share price	$2.46
Market cap	$281M
1-month price change	-21.41%
Sector	HealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.